Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.

Int J Cancer · 2018 · PMC5867246 · PMID 29277895

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an apparent trendno p-value reported

Although there was an apparent trend toward increased necrotic activities by a single agent and ENZ and CCX771 combination treatment, these effects were not statistically significant in the VCaP model (Figs. 6 g ).

also in 709 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.